Transcend: Initial outcomes from a posttraumatic stress disorder/substance abuse treatment programDONOVAN, Beverly; PADIN-RIVERA, Edgardo; KOWALIW, Sean et al.Journal of traumatic stress. 2001, Vol 14, Num 4, pp 757-772, issn 0894-9867Article

A Phase 1 Study of Weekly Everolimus (RAD001) in Combination With Docetaxel in Patients With Metastatic Breast CancerMOULDER, Stacy; GLADISH, Gregory; RIVERA, Edgardo et al.Cancer. 2012, Vol 118, Num 9, pp 2378-2384, issn 0008-543X, 7 p.Article

Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumorsELTING, Linda S; CANTOR, Scott B; MARTIN, Charles G et al.Cancer. 2003, Vol 97, Num 6, pp 1541-1550, issn 0008-543X, 10 p.Article

Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxelESMAELI, Bita; AMIN, Sapna; VALERO, Vicente et al.Journal of clinical oncology. 2006, Vol 24, Num 22, pp 3619-3622, issn 0732-183X, 4 p.Article

Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancerESMAELI, Bita; HORTOBAGYI, Gabriel N; ESTEVA, Francisco J et al.Ophthalmology (Rochester, MN). 2002, Vol 109, Num 6, pp 1188-1191, issn 0161-6420Article

Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancerBOOSER, Daniel J; ESTEVA, Francisco J; RIVERA, Edgardo et al.Cancer chemotherapy and pharmacology. 2002, Vol 50, Num 1, pp 6-8, issn 0344-5704, 3 p.Article

Paclitaxel in the multimodality treatment for inflammatory breast carcinomaCRISTOFANILLI, Massimo; BUZDAR, Aman U; UENO, Naoto et al.Cancer. 2001, Vol 92, Num 7, pp 1775-1782, issn 0008-543XArticle

A fatigue clinic in a comprehensive cancer center : Design and experiencesESCALANTE, Carmen P; GROVER, Tejpal; JOHNSON, Beth A et al.Cancer. 2001, Vol 92, Num 6, pp 1708-1713, issn 0008-543X, SUPConference Paper

A Phase 2 Study of A Fixed Combination of Uracil and Ftorafur (UFT) and Leucovorin Given Orally in A 3-times-daily Regimen to Treat Patients With Recurrent Metastatic Breast CancerHORTOBAGYI, Gabriel N; HEIM, William; HUTCHINS, Laura et al.Cancer. 2010, Vol 116, Num 6, pp 1440-1445, issn 0008-543X, 6 p.Article

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancerTHOMAS, Eva; TABERNERO, Josep; BASELGA, José et al.Journal of clinical oncology. 2007, Vol 25, Num 23, pp 3399-3406, issn 0732-183X, 8 p.Article

Outcomes and cost of deep venous thrombosis among patients with cancerELTING, Linda S; ESCALANTE, Carmelita P; COOKSLEY, Catherine et al.Archives of internal medicine (1960). 2004, Vol 164, Num 15, pp 1653-1661, issn 0003-9926, 9 p.Article

Evaluation of Paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trialBUZDAR, Aman U; SINGLETARY, S. Eva; HOLMES, Frankie A et al.Clinical cancer research. 2002, Vol 8, Num 5, pp 1073-1079, issn 1078-0432Article

A detailed evaluation of cardiac toxicity: A Phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancerGIORDANO, Sharon H; BOOSER, Daniel J; EWER, Michael et al.Clinical cancer research. 2002, Vol 8, Num 11, pp 3360-3368, issn 1078-0432, 9 p.Article

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplificationSEIDMAN, Andrew D; FORNIER, Monica N; GILEWSKI, Teresa et al.Journal of clinical oncology. 2001, Vol 19, Num 10, pp 2587-2595, issn 0732-183XArticle

Phase 3 Study Comparing the Use of Docetaxel on an Every-3-week Versus Weekly Schedule in the Treatment of Metastatic Breast CancerRIVERA, Edgardo; MEJIA, Jaime A; VALERO, Vicente et al.Cancer. 2008, Vol 112, Num 7, pp 1455-1461, issn 0008-543X, 7 p.Article

Clinicopathologic Characteristics and Prognostic Factors in 420 Metastatic Breast Cancer Patients With Central Nervous System MetastasisALTUNDAG, Kadri; BANDY, Melissa L; MIRZA, Nadeem Q et al.Cancer. 2007, Vol 110, Num 12, pp 2640-2647, issn 0008-543X, 8 p.Article

Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancerCHEDID, Silwan; RIVERA, Edgardo; FRYE, Debbie K et al.Cancer chemotherapy and pharmacology. 2006, Vol 57, Num 4, pp 540-544, issn 0344-5704, 5 p.Article

Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinomaPUSZTAI, Lajos; WAGNER, Peter; ROUZIER, Roman et al.Cancer. 2005, Vol 104, Num 4, pp 682-691, issn 0008-543X, 10 p.Article

Phase II study of Pegylated liposomal doxorubicin in combination with gemcitabine in Patients with metastatic breast cancerRIVERA, Edgardo; VALERO, Vicente; ARUN, Banu et al.Journal of clinical oncology. 2003, Vol 21, Num 17, pp 3249-3254, issn 0732-183X, 6 p.Article

Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxelIBRAHIM, Nuhad K; DESAI, Neil; ELLERHORST, Julie A et al.Clinical cancer research. 2002, Vol 8, Num 5, pp 1038-1044, issn 1078-0432Article

Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancerRIVERA, Edgardo; VALERO, Vicente; HORTOBAGYI, Gabriel N et al.Journal of clinical oncology. 2001, Vol 19, Num 6, pp 1716-1722, issn 0732-183XArticle